
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Esophageal Manifestations of Dermatological Diseases, Diagnosis and Management</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Esophageal Manifestations of Dermatological Diseases, Diagnosis and Management</strong></summary>
            <div>
                <ul><li>Article Type: Review Article</li><li>Journal: Curr Treat Options Gastroenterol</li><li>Publication Date: 2022 December; 20(4): 513–528.</li><li>DOI: 10.1007/s11938-022-00399-6</li><li>Purpose: Discuss diagnosis &amp; treatment of diseases affecting both skin &amp; esophagus.</li><li>Key Findings: Diagnosis often requires endoscopy + biopsy; some need serology, immunofluorescence, manometry, genetic testing. Many conditions successfully treated w/ systemic steroids + immunosuppressants. Strictures common → endoscopic dilation. Many diseases are pre-malignant → vigilance + surveillance endoscopy.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What percentage of scleroderma patients experience esophageal involvement?</li><li>2. Which dermatological condition affecting the esophagus is associated with a significantly increased risk of squamous cell carcinoma, with up to 92% of late-onset cases developing it by age 45?</li><li>3. In pemphigoid diseases, what is the reported risk for esophageal perforation after dilation, and when is dilation generally recommended?</li><li>4. What specific manometric finding is most common in scleroderma patients, observed in 56% of cases?</li><li>5. What percentage of patients with severe esophageal lichen planus were treated with systemic steroids in one case series?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Categorization of Diseases</strong></summary>
            <div>
                <ul><li>Diseases affecting skin &amp; esophagus grouped by underlying etiology.</li></ul>
                
        <details>
            <summary><strong>Autoimmune Conditions</strong></summary>
            <div>
                <ul><li>Group of diseases where the immune system mistakenly attacks healthy body tissues.</li></ul>
                
        <details>
            <summary><strong>Scleroderma</strong></summary>
            <div>
                <ul><li>Autoimmune, systemic connective tissue disorder.</li><li>Categorized into systemic sclerosis &amp; limited cutaneous scleroderma.</li><li>Esophageal involvement in ≈90% of patients.</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Raynaud’s phenomenon; telangiectasias; sclerodactyly; calcinosis; digital scars; hyperpigmentation; contractures.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Manifestations &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Dysmotility → pathologic GERD.</li><li>Consequences: peptic strictures, erosive esophagitis, Barrett’s esophagus, adenocarcinoma.</li><li>Endoscopic findings: telangiectasias.</li></ul>
                
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Heartburn; dysphagia; chest pain; regurgitation; weight loss.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Serology may be helpful.</li><li>HREM abnormalities common (75–80%).</li></ul>
                
        <details>
            <summary><strong>Serology</strong></summary>
            <div>
                <ul><li>Associated antibodies: anti-nuclear antibodies; anti-topoisomerase antibodies; anti-RNA polymerase III antibodies; anti-centromere antibodies.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>High-Resolution Esophageal Manometry (HREM)</strong></summary>
            <div>
                <ul><li>Common findings: Absent contractility (56% most common); Ineffective Esophageal Motility (IEM) (10%).</li><li>Specific findings: hypomotility of smooth muscle esophagus (distal ⅔); hypotonic lower esophageal sphincter (LES).</li><li>Classic scleroderma esophagus (absent contractility w/ ↑ esophagogastric pressures) in 33% of patients; normal manometry in 26%.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Individualized based on symptom severity.</li><li>Focus on underlying esophageal dysmotility &amp; reflux predisposition.</li></ul>
                
        <details>
            <summary><strong>Medical Therapy</strong></summary>
            <div>
                <ul><li>Proton pump inhibitors (PPIs): mainstay of treatment; high-dose preferred due to suboptimal response to conventional doses.</li><li>Alginates: added for breakthrough symptoms w/ incomplete PPI response.</li><li>Prokinetics (erythromycin, metoclopramide, domperidone): controversial; limited substantive data.</li><li>Buspirone, bethanechol, pyridostigmine: trial for severe dysphagia w/o obvious stricture.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Therapy</strong></summary>
            <div>
                <ul><li>Endoscopy: warranted for dysphagia to assess for stricture.</li><li>Endoscopic dilation: performed if stricture encountered; no data suggests one method &gt; another.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Surgical Considerations</strong></summary>
            <div>
                <ul><li>Antireflux surgeries: considered w/ caution → frequent underlying esophageal dysmotility + predisposition to post-fundoplication dysphagia.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Dermatomyositis</strong></summary>
            <div>
                <ul><li>Autoimmune disorder; arises in genetically susceptible individuals after unknown environmental insult.</li><li>Cutaneous changes in 30–40% adults, 95% children.</li><li>Dysphagia in ≈15–50% of patients.</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Pathognomonic: Gottron’s papules (lichenoid erythematous papules over knuckles); Gottron’s sign (erythematous patches over extensor surfaces).</li><li>Heliotrope rash; Shawl sign; Periungual telangiectasias.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Manifestations &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Frequent abnormal esophageal motility.</li><li>Consequences: Barrett’s esophagus, adenocarcinoma.</li></ul>
                
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Dysphagia; heartburn; regurgitation; odynophagia.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Evaluation of skin, muscle strength, &amp; lab results.</li></ul>
                
        <details>
            <summary><strong>Serology</strong></summary>
            <div>
                <ul><li>Elevated enzymes: CK, LDH, AST, aldolase.</li><li>Dermatomyositis specific autoantibodies: Mi2, TIF1, MDA5, NXP2, SAE.</li><li>Antisynthetase autoantibodies: Jo-1, PL-7, PL-12, EJ, OJ.</li><li>Other connective tissue disease antibodies: ANA, Ro/La, dsDNA, anti-SM, Scl-70.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Diagnostics for Dysphagia</strong></summary>
            <div>
                <ul><li>Endoscopy; barium studies (esophagram / modified barium swallow); HREM.</li><li>HREM findings: frequently normal; may display ineffective esophageal motility, absent contractility, or jackhammer esophagus.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Depends on disease severity &amp; organ systems involved.</li></ul>
                
        <details>
            <summary><strong>Medical Therapy</strong></summary>
            <div>
                <ul><li>PPIs: for reflux symptoms.</li><li>Systemic steroids; immunosuppressants.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cancer Risk &amp; Surveillance</strong></summary>
            <div>
                <ul><li>↑ risk of developing cancer; prevalence ≈20%.</li><li>Risk highest within 1 year after diagnosis, remains elevated 5 years after.</li><li>Patients should receive age-appropriate screening &amp; symptom-targeted diagnostics.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pemphigus &amp; Pemphigoid Diseases</strong></summary>
            <div>
                <ul><li>Autoimmune skin disorders characterized by autoantibodies.</li><li>Pemphigus: targets desmosomes → loss of cell-to-cell adhesion.</li><li>Pemphigoid: targets basement membrane.</li></ul>
                
        <details>
            <summary><strong>Pemphigus Vulgaris</strong></summary>
            <div>
                <ul><li>Most common form of pemphigus.</li><li>Patients often display painful oropharyngeal lesions preceding cutaneous manifestations.</li><li>Esophagus involved in 47–68% of patients.</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Intraepithelial skin &amp; mucous membrane vesiculobullous lesions.</li><li>Nikolsky’s sign positive: mechanical contact → exfoliation of outermost layer.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Manifestations &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Esophagus may be involved w/o affecting skin.</li><li>Proximal esophagus more likely affected.</li><li>Esophageal lining may easily detach during endoscopy (Nikolsky’s sign positive).</li><li>Endoscopic findings: strictures, erosions, ulcers, blisters, vesiculobullous lesions, furrows throughout esophagus.</li></ul>
                
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Odynophagia; dysphagia; weight loss.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Histologic features similar to dermatological features.</li></ul>
                
        <details>
            <summary><strong>Pathology</strong></summary>
            <div>
                <ul><li>Acantholytic cells in basal layer w/ “tombstone” appearance; intraepithelial bullae.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Immunofluorescence</strong></summary>
            <div>
                <ul><li>Autoantibody deposition of IgG, IgA, &amp; C3 complement in a net-like pattern.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Systemic steroids &amp; immunotherapy are mainstays.</li><li>Patients requiring ≥3 treatment modalities more likely to receive EGD &amp; present w/ dysphagia.</li><li>Good response to treatment: complete symptom resolution &amp; pathology on EGD reported.</li></ul>
                
        <details>
            <summary><strong>Medical Therapy</strong></summary>
            <div>
                <ul><li>Systemic corticosteroids: 100% resolution on endoscopy in one study of oral pemphigus w/ esophageal involvement.</li><li>Aggressive treatment (rituximab, IVIG): for non-responders to corticosteroids → better disease control in refractory cases.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Therapy for Strictures</strong></summary>
            <div>
                <ul><li>Endoscopic dilation: w/ balloons or bougies.</li><li>Stricturoplasty; stenting.</li><li>Intralesional steroid injection + topical steroids: successful for recurrent strictures failing multiple balloon dilations (case report).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pemphigoid Disorders (Mucous Membrane Pemphigoid - MMP)</strong></summary>
            <div>
                <ul><li>Caused by autoantibodies targeting basement membrane.</li><li>Characterized by sub-epidermal bullae; Nikolsky’s sign negative.</li><li>MMP more frequently displays oral &amp; ocular lesions &gt; skin manifestations.</li><li>Esophageal involvement in 4–11% of patients w/ MMP.</li><li>Diagnosis of esophageal involvement may be delayed (17–156 months reported).</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Sub-epidermal bullae; Nikolsky’s sign negative.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Manifestations &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Esophagus may be involved w/o affecting skin.</li><li>Proximal esophagus more likely affected.</li><li>Esophageal lining may easily detach during endoscopy (Nikolsky’s sign positive).</li><li>Endoscopic findings: esophageal webs, stenosis, erosions, exudates w/ fibrin, subepithelial hematomas.</li></ul>
                
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Odynophagia; dysphagia; weight loss.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Clinical findings, dermal pathology, immunofluorescence.</li><li>Esophageal biopsy infrequently displays same immunofluorescent patterns/markers.</li></ul>
                
        <details>
            <summary><strong>Histology</strong></summary>
            <div>
                <ul><li>Skin: sub-epithelial blister formation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Immunofluorescence</strong></summary>
            <div>
                <ul><li>Linear deposits of IgG at basement membrane (anti-BP-180, antiBP-230).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Distinguish active vs. cicatricial (scarred) lesions; active lesions require medical therapy.</li><li>Endoscopy only in symptomatic patients &amp; preferably by experienced providers → fragile mucosa.</li><li>↑ risk for esophageal perforation after dilation.</li></ul>
                
        <details>
            <summary><strong>Medical Therapy</strong></summary>
            <div>
                <ul><li>Systemic steroids; immunosuppressants (rituximab, mycophenolate, cyclophosphamide).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Therapy for Strictures</strong></summary>
            <div>
                <ul><li>Esophageal dilation: may be required.</li><li>Balloon dilation: successful in a case series of 12 MMP patients; recommended *only after* disease adequately controlled w/ medical therapy.</li><li>Less likely successful in severe dysphagia w/ uncontrolled disease.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Infectious Conditions</strong></summary>
            <div>
                <ul><li>Diseases caused by pathogenic microorganisms affecting both skin &amp; esophagus.</li></ul>
                
        <details>
            <summary><strong>HSV/CMV/HIV Esophagitis</strong></summary>
            <div>
                <ul><li>Viral esophagitis typically presents w/ odynophagia &amp; dysphagia in immunosuppressed individuals.</li><li>HSV can occur in immunocompetent individuals.</li></ul>
                
        <details>
            <summary><strong>Herpes Simplex Virus (HSV) Esophagitis</strong></summary>
            <div>
                <ul><li>Typically presents in distal esophagus.</li><li>Endoscopic findings: multiple small, painful, discrete ulcers; punched-out ulcers w/ yellow-rim &amp; vesicles.</li><li>Histology: intranuclear eosinophilic inclusions (Cowdry A bodies).</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Cold sores; genital herpes; herpetic whitlow; herpetic eczema.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Odynophagia; dysphagia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Double-contrast esophagography can assist; upper endoscopy w/ biopsy necessary for tissue diagnosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>Acyclovir, valacyclovir, or famciclovir.</li><li>Duration: 7–10 days for immunocompetent; 14–21 days for immunocompromised.</li><li>Prophylactic antiviral therapy: may be indicated in immunocompromised individuals.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Cytomegalovirus (CMV) Esophagitis</strong></summary>
            <div>
                <ul><li>Classically characterized by fewer, larger ulcers.</li><li>Endoscopic findings: more common in distal esophagus; deep, longitudinal, &amp; linear ulcers.</li><li>Histology: large eosinophilic or basophilic intranuclear inclusions (H&amp;E staining).</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Petechiae; morbilliform rashes; cutaneous vasculitis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Odynophagia; dysphagia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Double-contrast esophagography can assist; upper endoscopy w/ biopsy necessary for tissue diagnosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>Ganciclovir or valganciclovir.</li><li>IV ganciclovir daily for 3–6 weeks.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Human Immunodeficiency Virus (HIV) Esophagitis</strong></summary>
            <div>
                <ul><li>Classically characterized by fewer, larger ulcers.</li><li>Endoscopic findings: deep ulcers in middle of esophagus.</li><li>Histology: eosinophilic infiltrate; inflammatory infiltrate.</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Kaposi sarcoma; anal papillomas; candida; eosinophilic folliculitis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Odynophagia; dysphagia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Double-contrast esophagography can assist; upper endoscopy w/ biopsy necessary for tissue diagnosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>Steroids.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Inflammatory Conditions</strong></summary>
            <div>
                <ul><li>Diseases characterized by inflammation affecting both skin &amp; esophagus.</li></ul>
                
        <details>
            <summary><strong>Lichen Planus</strong></summary>
            <div>
                <ul><li>Inflammatory mucocutaneous disease of unknown etiology.</li><li>May be associated w/ infections, medications, or autoimmune factors.</li><li>Esophageal lichen planus disproportionately affects women.</li><li>Esophageal involvement seen in 26% to 50% of patients.</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Pruritic, violaceous papules &amp; plaques (most commonly over extensor surfaces).</li><li>Oral lichen planus: white lace-like pattern (Wickham striae).</li><li>Skin, nails, hair, genital, &amp; oral mucosa may be involved.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Manifestations &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Many patients w/ esophageal involvement are asymptomatic.</li><li>Esophageal strictures are a frequent finding.</li><li>Mucosal detachment during endoscopy/dilation may be a specific sign.</li></ul>
                
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Dysphagia; odynophagia; heartburn; regurgitation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Findings</strong></summary>
            <div>
                <ul><li>Concentric rings, mucosal edema, white plaques (similar to eosinophilic esophagitis).</li><li>Other findings: loss of vascularity, friability, erythema; ringed esophagus; peeling mucosa; papular lesions; submucosal plaques; white papules.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Consider characteristic skin &amp; mucosal findings, endoscopy, histology, &amp; immunofluorescence.</li></ul>
                
        <details>
            <summary><strong>Histology</strong></summary>
            <div>
                <ul><li>Lichenoid inflammation; detachment of epithelium; necrotic keratinocytes (Civatte bodies).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Immunofluorescence</strong></summary>
            <div>
                <ul><li>Fibrin deposition along basement membrane.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Relapse rates after treatment may be as high as 85%.</li></ul>
                
        <details>
            <summary><strong>Medical Therapy</strong></summary>
            <div>
                <ul><li>Severe disease: systemic steroids followed by maintenance w/ swallowed steroids (44% of severe cases in one series).</li><li>Milder disease: often no systemic/topical steroids needed; swallowed steroids if necessary.</li><li>Immunomodulators: azathioprine, tacrolimus, cyclosporine, rituximab (some patients).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Therapy</strong></summary>
            <div>
                <ul><li>Endoscopic dilation: for dysphagia; can lead to rapid improvement.</li><li>Caution: Koebner phenomenon (new lesions after trauma) described after dilation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Malignancy Risk &amp; Surveillance</strong></summary>
            <div>
                <ul><li>Squamous Cell Carcinoma (SCC) reported in long-standing esophageal lichen planus.</li><li>6% of patients developed esophageal SCC in one study.</li><li>Periodic surveillance endoscopy w/ mucosal biopsies should be considered.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Crohn’s Disease</strong></summary>
            <div>
                <ul><li>Idiopathic inflammatory bowel disease w/ genetic &amp; environmental influences.</li><li>Incidence: ≈3.1 to 14.6 per 100,000 individuals/year.</li><li>Esophageal Crohn’s disease is rare; higher prevalence in children &amp; potentially racial/ethnic minority populations.</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Pyoderma gangrenosum; erythema nodosum; fistulas; Sweet syndrome; oral aphthous ulcers.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Manifestations &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Most frequently involves distal esophagus.</li><li>Early stages: erythema, edema, aphthous ulcers, granularity.</li><li>Later stages: ulcers, strictures, fistulas.</li></ul>
                
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Dysphagia (54%); odynophagia (33%); reflux (25%); chest pain (13%).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Suspect in patient w/ Crohn’s &amp; atypical esophageal findings.</li><li>May be difficult due to potential for multiple diagnoses (GERD, Eosinophilic Esophagitis).</li><li>Screening endoscopy: recommended in all children newly diagnosed w/ Crohn’s (vs. adults).</li></ul>
                
        <details>
            <summary><strong>Histology</strong></summary>
            <div>
                <ul><li>May reveal non-caseating granulomas (frequently absent).</li><li>Intraepithelial lymphocytes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Similar to Crohn’s w/o esophageal involvement.</li><li>Stepwise approach often used.</li></ul>
                
        <details>
            <summary><strong>Medical Therapy</strong></summary>
            <div>
                <ul><li>PPIs; H2 blockers; systemic steroids (often utilized for superior efficacy in upper GI tract); 5-aminosalicylates.</li><li>Swallowed topical steroids: effectively treat esophageal Crohn’s.</li><li>Immunosuppressants; biologics (e.g., infliximab).</li><li>Infliximab: effective for patients failing other modalities; complete clinical symptom resolution in 5/5 patients in one series; combination w/ dilation &amp; immunomodulators effective for structuring disease.</li><li>Successful treatment of gastro-esophageal fistula w/ infliximab after failure of other therapies (1 patient).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Therapy for Strictures</strong></summary>
            <div>
                <ul><li>Alternative between medical &amp; surgical therapy.</li><li>Balloon dilation: first-line for non-complex strictures (&lt;4–5 cm), single strictures, or strictures w/o pre-stenotic dilation.</li><li>Endoscopic electroincision (stricturotomy &amp; strictureplasty): utilized if repeat balloon dilation unsuccessful.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Surgical Therapy</strong></summary>
            <div>
                <ul><li>Rarely required: esophagectomy for fistulas w/ tracheobronchial tree, paraoesophageal abscesses, mediastinitis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Genetic Conditions</strong></summary>
            <div>
                <ul><li>Inherited disorders affecting both skin &amp; esophagus.</li></ul>
                
        <details>
            <summary><strong>Epidermolysis Bullosa</strong></summary>
            <div>
                <ul><li>Rare genetic syndrome w/ blistering mucocutaneous lesions.</li><li>Defect in anchoring protein between epidermis &amp; dermis.</li><li>Esophageal involvement normally associated w/ autosomal recessive inheritance &amp; dystrophic epidermolysis bullosa subtype.</li><li>Seen in children.</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Blistering lesions; erosions; scars; milia; sometimes missing nails.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Manifestations &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Most notable for development of esophageal strictures.</li><li>Proximal esophageal strictures seen 2x as frequently as distal strictures.</li><li>Microstomia due to oropharyngeal scarring.</li></ul>
                
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Dysphagia; odynophagia; malnutrition.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Route light microscopy not recommended (difficult to interpret).</li><li>Immunofluorescence antigenic mapping &amp; transmission electron microscopy: provide diagnostic info on subtype.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Esophageal Stricture</strong></summary>
            <div>
                <ul><li>Dietary modification; careful balloon dilation; placement of gastrostomy tube for nutritional purposes.</li><li>Dedicated anesthesia team: may assist during endoscopy for IV catheter placement &amp; potential intubation.</li></ul>
                
        <details>
            <summary><strong>Dietary Management</strong></summary>
            <div>
                <ul><li>Encouragement of soft foods; avoidance of hot foods &amp; hyperalimentation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Dilation Challenges</strong></summary>
            <div>
                <ul><li>Esophageal dilation may be attempted via retrograde approach from gastrostomy tube if microstomia present.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Cowden Syndrome</strong></summary>
            <div>
                <ul><li>Autosomal dominant disease secondary to PTEN gene mutation.</li><li>Prevalence: ≈1 in 200,000 to 1 in 250,000.</li><li>Dominant features: multiorgan hamartomas &amp; ↑ risk of multiple malignancies.</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Near universal (90% affected individuals): trichilemmomas (hamartomas of hair follicles); mucocutaneous papillomas.</li><li>Lipomas; fibromas.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastrointestinal Manifestations</strong></summary>
            <div>
                <ul><li>Polyposis throughout GI tract: hamartomatous polyps, hyperplastic changes, gangliocytomas, adenomas.</li><li>Esophageal lesions: glycogenic acanthosis (benign finding, associated w/ GERD, incidental in ≈3.5% endoscopies).</li><li>Glycogenic acanthosis observed in ↑80% of patients w/ Cowden syndrome.</li></ul>
                
        <details>
            <summary><strong>Endoscopic Findings</strong></summary>
            <div>
                <ul><li>Hamartomatous polyps; hyperplastic changes; gangliocytomas; adenomas.</li><li>Glycogenic acanthosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Made through clinical findings w/ specific criteria.</li><li>PTEN genetic testing confirms diagnosis.</li></ul>
                
        <details>
            <summary><strong>Pathognomonic Criteria</strong></summary>
            <div>
                <ul><li>Trichilemmomas; acral keratosis; papillomatous papules; mucosal lesions.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Major Criteria</strong></summary>
            <div>
                <ul><li>Breast, thyroid, endometrial carcinoma; macrocephaly; Lhermitt-Duclos disease.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Minor Criteria</strong></summary>
            <div>
                <ul><li>Other thyroid lesions; Intelligence Quotient &lt;75; GI hamartomas; fibrocystic disease of breasts</li><li>, lipomas, fibromas, genitourinary tumors.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Confirmation</strong></summary>
            <div>
                <ul><li>Pathognomonic skin findings; OR two major criteria; OR one major + 3 minor criteria; OR four minor criteria.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopist Consideration</strong></summary>
            <div>
                <ul><li>Consider Cowden syndrome if glycogenic acanthosis observed w/ colonic polyposis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management &amp; Surveillance</strong></summary>
            <div>
                <ul><li>Close follow-up required due to associated malignancies.</li></ul>
                
        <details>
            <summary><strong>Cancer Screening</strong></summary>
            <div>
                <ul><li>Colonoscopy: age 35 or 10 years before first-degree relative&#x27;s colorectal cancer diagnosis.</li><li>Surveillance endoscopy: every 1–5 years depending on polyp number &amp; characteristics.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Focal Dermal Hypoplasia (Goltz Syndrome)</strong></summary>
            <div>
                <ul><li>Rare X-linked dominant genetic disorder; ≈300 cases reported worldwide.</li><li>9:1 female to male ratio (often fatal in utero for males).</li><li>Caused by PORCN gene mutation → defective mesodermal &amp; ectodermal development.</li><li>Patients can present w/ dysphagia secondary to esophageal papillomas.</li><li>Many patients have GERD; theorized to contribute to esophageal papilloma formation.</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Skin nodules; pigment changes; abnormal nails; dysmorphic facial features; telangiectasias.</li><li>Mucocutaneous papillomas over mouth, nose, larynx, anus, genitals.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Skeletal Manifestations</strong></summary>
            <div>
                <ul><li>Syndactyly; ectrodactyly; malformations of truncal skeleton.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Manifestations &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Papillomas.</li></ul>
                
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Dysphagia; heartburn.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Combination of characteristic clinical findings (limb malformations, skin findings) &amp; molecular genetics.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Management &amp; Surveillance</strong></summary>
            <div>
                <ul><li>Patients should be monitored for GERD &amp; dysphagia symptoms.</li></ul>
                
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>Argon plasma coagulation: debulk papillomas &amp; successfully relieve dysphagia (one case).</li><li>PPI: for GERD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Malignancy Risk</strong></summary>
            <div>
                <ul><li>Malignant conversion of esophageal papillomas to SCC described, but not frequently observed.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Tylosis</strong></summary>
            <div>
                <ul><li>Rare genetic disorder; epidermolytic palmoplantar hyperkeratosis.</li><li>↑ risk of developing SCC of the esophagus.</li><li>Associated w/ RHBDF2 gene; autosomal dominant inheritance.</li><li>Prevalence: &lt;1 in 1,000,000.</li><li>Classified into early onset (&lt;1 year) &amp; late onset (age 5–15).</li></ul>
                
        <details>
            <summary><strong>Dermatological Manifestations</strong></summary>
            <div>
                <ul><li>Skin plaques of hands &amp; feet; fissures on extremities; ↑ risk of tinea pedis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Manifestations &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Early stages: may be asymptomatic.</li><li>Esophageal neoplasms most commonly discovered in lower ⅔ of esophagus.</li></ul>
                
        <details>
            <summary><strong>Symptoms</strong></summary>
            <div>
                <ul><li>Dysphagia; odynophagia; weight loss (symptoms of esophageal cancer).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Findings</strong></summary>
            <div>
                <ul><li>White polypoid lesions; diffuse hyperkeratosis; longitudinal grooves; strictures.</li><li>No correlation between endoscopic findings &amp; disease progression due to rarity.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Combination of family history, skin findings, endoscopic features, &amp; evidence of RHBDF2 gene mutation.</li><li>Esophageal histology: non-specific; keratohylaine granules, parakeratosis, inflammatory infiltrate.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Management &amp; Surveillance</strong></summary>
            <div>
                <ul><li>Late onset tylosis: very high risk of developing esophageal cancer (40–92%).</li><li>Patients develop esophageal cancer @ average age of 45 years.</li></ul>
                
        <details>
            <summary><strong>Cancer Surveillance</strong></summary>
            <div>
                <ul><li>Surveillance endoscopy: starting @ age 30, every 1–3 years.</li><li>Family members w/ tylosis: screened w/ biopsy of suspicious lesions + quadratic biopsies of upper, middle, &amp; lower esophagus.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Risk Factor Modification</strong></summary>
            <div>
                <ul><li>Counseling to avoid SCC risk factors: alcohol &amp; smoking cessation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Potential Therapies</strong></summary>
            <div>
                <ul><li>Carotenoids: may delay progression or revert lesions to normal (evidence).</li><li>Dermatological manifestations: treated w/ footwear, emollients, retinoids, early treatment of fissures &amp; infections.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Genetic Counseling</strong></summary>
            <div>
                <ul><li>Family members should receive genetic counseling if tylosis diagnosed in an individual.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>General Diagnostic &amp; Management Principles</strong></summary>
            <div>
                <ul><li>Connecting dermatological conditions to dysphagia of unknown etiology is important.</li><li>Diagnosis often relies on characteristic clinical features, endoscopy, &amp; histology.</li></ul>
                
        <details>
            <summary><strong>Diagnostic Modalities by Etiology</strong></summary>
            <div>
                <ul><li>Autoimmune conditions: utilize serology.</li><li>Infectious conditions: diagnosed w/ endoscopy + biopsy; treated w/ antimicrobials.</li><li>Inflammatory conditions: often rely heavily on clinical features.</li><li>Genetic diseases: rely on clinical features; confirmed w/ genetic testing.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Common Treatment Strategies</strong></summary>
            <div>
                <ul><li>Steroids; immunosuppressants; proton pump inhibitors (PPIs).</li><li>Esophageal strictures: common result → may require endoscopic treatment w/ dilation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Malignancy Risk</strong></summary>
            <div>
                <ul><li>Many diseases are pre-malignant → proper cancer surveillance &amp; vigilance is important.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
